alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › vaccine

vaccine

4 studies tagged vaccine, dated 2014-02-20 to 2026-07-22. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-cognitively impaired participants: prelude for secondary preventive therapy in preclinical AD 2026-07-22
  2. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial 2026-05-19
  3. A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies 2016-04-06

Studies

4 studies carry this tag.

Date range

2014 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Alzheimer's research & therapy 1
  • Journal of neurochemistry 1
  • Molecular neurodegeneration 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-cognitively impaired participants: prelude for secondary preventive therapy in preclinical AD

    ✓ Peer-reviewed alzhub usefulness score 81 out of 100. Molecular neurodegeneration 2026-07-22 Treatments

    However, all Aβ vaccines tested so far in people with disease have faced significant challenges, primarily due to inadequate immunogenicity and insufficient antibody titers required to clear, reduce, or slow amyloid pathology.

  2. Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer's disease: randomised, controlled trial

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Alzheimer's research & therapy 2026-05-19 Treatments

    In this small Phase 1 study in early AD, ALZ‑101 was not associated with clear safety signals and elicited strong, durable Aβ‑specific antibody responses.

  3. A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 2016-04-06 Treatments

    The promising results obtained with aducanumab and solanezumab against Alzheimer's disease (AD) strengthen the vaccine approach to prevent AD, despite of the many clinical setbacks.

  4. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-02-20 Treatments

    AV-1959 is a promising vaccine candidate capable of producing therapeutically potent anti-amyloid antibody in a broader population of vaccinated subjects with high MHC class II gene polymorphisms.

All topic tags with their study counts